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Background: Breast-cancer incidence and mortality have been increasing in Japan. Japanese-specific clinical validity
and utility data for the 21-gene assay (Oncotype DX® Breast Cancer Assay; Genomic Health, Inc., Redwood City, USA)
are now available. The objective of this study was to evaluate the cost-effectiveness of the 21-gene assay for the
guidance of adjuvant chemotherapy decisions in estrogen-receptor–positive, lymph-node–negative, early-stage
breast cancer patients, from the Japanese societal perspective.
Methods: The recurrence risk group distribution by the 21-gene assay result and the assay’s influence on adjuvant
chemotherapy recommendations were obtained from a study of 104 patients. A state-transition cohort (Markov)
model tracked time from surgery until distant recurrence and from distant recurrence to death. Adjuvant
chemotherapy benefit by 21-gene assay risk group was based on published clinical validation studies. Direct
and indirect medical costs were obtained from the referral centers. Utilities associated with progression and
chemotherapy-related adverse events were extracted from literature. Sensitivity analyses assessed the key drivers
and robustness of the primary outcomes.
Results: The 21-gene assay identified 48% of patients as low-risk, 36% as intermediate-risk, and 16% as high-risk.
Total acute chemotherapy-related costs decreased by ¥154,066 due to less adjuvant chemotherapy usage. In the
high-risk group, adjuvant chemotherapy use increased 18%, leading to survival benefits. Chemotherapy use overall
decreased by 19%. Monitoring costs increased by ¥3,744 but recurrence costs declined by ¥46,113 per patient. Use
of the 21-gene assay increased quality-adjusted–life-years (QALYs) by 0.241 per patient on average; the net cost per
QALY gained was ¥636,752 ($6,368).
Conclusions: The 21-gene assay for women with estrogen-receptor–positive, lymph-node–negative, early-stage
breast cancer is projected to be cost-effective in Japan.
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Breast cancer is the most common cancer among Japanese
women, with approximately 40,000 women diagnosed
every year [1-3]. Although the breast-cancer–specific
mortality rate is declining in the United States and other
Western countries, it is rising in Japan [4]. At diagnosis, at
least 83% of breast cancer in Japan present with early-
stage disease (stages 0, I, II, or IIIa) [5,6]; more than 60%
have no lymph node involvement (LN-), and 74% have
estrogen-receptor–positive (ER+) breast cancer.
Guidelines issued by the National Comprehensive
Cancer Network (NCCN) and the expert panel at the
2011 St. Gallen International Breast Cancer Conference
indicate that patients with ER+, LN- early-stage breast
cancer (ESBC) have the options of systemic adjuvant treat-
ment with either endocrine therapy and/or chemotherapy
[7,8]. They recommend that clinicians consider selecting
candidates for adjuvant chemotherapy to prevent distant
recurrence on the basis of clinical and pathologic features,
such as patient age, tumor size, degree of lymph node in-
volvement, and tumor differentiation. The potential risk
reduction in distant recurrence must be weighed against
the risks of adverse events with adjuvant chemotherapy; at
least 10% of patients experience serious or life-threatening
adverse effects with chemotherapy treatment [9].
The 21-gene assay (Oncotype DX® Breast Cancer Assay;
Genomic Health, Inc., Redwood City, USA) has been
shown to predict local and distant recurrence risk, sur-
vival, and chemotherapy benefit in ER+ ESBC [10-16].
The 21-gene assay has been commercially available in
Japan since 2007. Two observational studies published in
2010 support the validation of the assay in Japan as a
strong predictor of distant recurrence risk [3,17]. Toi et al.
conducted a prospective analysis of previously archived
tumor samples from 200 women who had ER+, LN- ESBC
and had undergone tamoxifen treatment at eight high-
volume centers throughout Japan [17]. The distant recur-
rence rate at 10 years among Japanese women with ER+,
LN- ESBC was 9.6% on average, but as high as 24.8% in
the high-risk group. Yorozuya et al. conducted a retro-
spective, case–control study in 40 patients who had sur-
gery for ER+, LN- ESBC in Japan [3]. They found that the
21-gene assay had stronger predictive power than tumor
histological grade.
A study at tertiary referral centers in Tokyo and Saitama,
Japan evaluated 104 women with ER+ ESBC, either with-
out nodal involvement or with micrometastases, and
showed that the 21-gene assay changed 33% of the adju-
vant chemotherapy treatment recommendations, resulting
in a net 19% absolute reduction in chemotherapy use [18].
Using the decision impact data from Japanese clinical prac-
tice, this study aimed to evaluate the cost-effectiveness of
the 21-gene assay compared to traditional prognostic
indicators for the guidance of adjuvant chemotherapydecisions in ER+, LN- ESBC patients from a societal per-
spective in Japan.
Methods
This analysis considered Japanese women with ER+, LN-
(including micrometastases) ESBC who were eligible for
treatment with adjuvant chemotherapy after having under-
gone surgery for primary tumor removal and lymph node
dissection.
Analytical framework
Outcomes and costs were assessed from a Japanese societal
perspective from surgery to death using a state-transition
cohort (Markov) model (Figure 1). The primary compara-
tor was clinical practice where risk assessment for 10-year
distant recurrence was based on traditional clinicopa-
thological factors recommended in guidelines [7]. The
intervention was use of the 21-gene assay (Oncotype DX®
Breast Cancer Assay; Genomic Health, Inc., Redwood City,
USA) to stratify patients into 3 risk groups – low, inter-
mediate, or high. The probabilities of recommendations in
favor of adjuvant chemotherapy before and after availability
of the patients’ 21-gene assay results were obtained from
the tertiary referral center study [18]. Thereafter, the model
followed the incidence of distant recurrence, breast-
cancer–related mortality, and non–breast-cancer–related
mortality.
Direct medical costs were included for the 21-gene assay,
adjuvant chemotherapy, surveillance (2 outpatient visits
per year), adverse events and distant recurrence. Indirect
costs included travel expenses, and patient time for travel
and treatment. All costs are reported in 2013 Japanese Yen
(JPY, ¥). Cost data from previous years were adjusted using
consumer price indices for medical services and public
transportation published by the Statistics Bureau of Japan
[19], and wage indices published by the Japanese Ministry
of Health, Labour and Welfare [20]. Summaries are pro-
vided selectively in United States Dollars (USD, $; conver-
sion rate: 100 JPY = 1 USD) for comparison.
Costs and benefits of treatment were discounted at a 3%
annual rate, which is in accordance with recommenda-
tions from the International Society for Pharmacoeco-
nomics and Outcomes Research (ISPOR) [21] and has
been used in prior cost-effectiveness studies in Japan
[22,23]. Inputs were varied individually in a one-way
sensitivity analysis to evaluate the effects of each input
variable’s uncertainty on the assay’s incremental cost-
effectiveness ratio (cost per QALY gained).
Data sources and assumptions
Impact of the 21-gene assay score on recommendations to
use adjuvant chemotherapy
The tertiary referral centers study found that recom-
mendations for adjuvant chemotherapy decreased by
Figure 1 Markov diagram. The level of recurrence risk is based on the 21-gene assay. Quotation marks indicate values unknown to physicians
and patients. Abbreviation: aCT, adjuvant chemotherapy.
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[18]. None of the women identified as having low distant
recurrence risk were recommended to adjuvant chemo-
therapy after receiving their 21-gene assay results, down
from 32% prior to testing. In the intermediate risk group,
19% fewer were recommended adjuvant chemotherapy,
whereas recommendations increased by 18% in the high
risk group.
Probability of recurrence, mortality, and adjuvant
chemotherapy adverse events
Estimates of the baseline recurrence risk in Japan by the
21-gene assay’s risk groups were extracted from Toi
et al., who studied the clinical validity of the assay in a
Japanese population of 200 women with LN- ESBC




Patients recommended by physicians to adjuvant
chemotherapy, n (%)
Prior to assay After assay Change
All 48 (46.2) 28 (26.9) −20 (−19.2)
Low-risk 16 (32.0) 0 (0.0) −16 (−32.0)
Intermediate-risk 18 (48.6) 11 (29.7) −7 (−18.9)
High-risk 14 (82.4) 17 (100.0) 3 (17.6)
*Risk group determined by the 21-gene assay. Risk groups: zero to 17 is
low-risk, 18 to 30 is intermediate-risk, greater than 30 is high-risk.
Source: Yamauchi et al. Clin Breast Cancer 2013 [18].previously reported for women from the US and UK
[11,14]. Data on the benefit of chemotherapy by 21-gene
assay risk group were extracted from a separate vali-
dation study of patients from NSABP B-20 [15].
Japanese-specific risks of grade 1, 2, or 3 adverse events
were extracted from unpublished data from St. Luke’s
Hospital analyzed by Tsugawa et al. The risk of fatal
toxicity from adjuvant chemotherapy was extracted from
Hillner and Smith [24]. The annual risk of dying from
non–breast-cancer–related causes was based on popula-
tion mortality rate data in Japan [25]. The annual risk of
dying from breast-cancer–related causes after recurrence
was extracted from previous models [22,23].
Costs
The price of the 21-gene assay was set equal to the list
price in Japan, (¥350,000). The cost of chemotherapy,
¥561,813, was based on data from one of the tertiary
referral centers, St. Luke’s Hospital in Tokyo, Japan
(Table 2). The total direct medical costs of salvage treat-
ment and palliative care from the time of distant re-
currence to time of death in Japan is ¥4,710,584 [22],
representing an annual cost after recurrence equal to
¥2,405,924. Costs to patients and payers to manage
adverse events were obtained from the tertiary referral
center study and weighted by the proportion of patients
who experienced the event. Additional indirect patient
time and transportation costs were derived as the sum
of lost time (valued based on average hourly wage in
Table 2 Model inputs
Parameter Mean Sensitivity analysis Source
Low High
Baseline recurrence risk by 21-gene assay risk group
Japan
Low-risk 3.3% 1.1% 10.0% [17]
Intermediate-risk 0.0% 0.0% 0.0% [17]
High-risk 24.8% 15.7% 37.8% [17]
US and UK
Low-risk 5.4% 3.6% 8.5% [11,14]
Intermediate-risk 13.7% 8.6% 20.0% [11,14]
High-risk 29.2% 21.6% 37.2% [11,14]
Relative reduction of recurrence with aCT by 21-gene assay risk group
Low-risk 0% 0% 54% [15]
Intermediate-risk 39% 0% 76% [15]
High-risk 74% 47% 87% [15]
Costs*
21-gene assay ¥350,000($3,500) ¥262,500 ¥437,500 List price
Associated with aCT
Drugs ¥561,813($5,618) ¥280,907 ¥1,500,000 St. Luke’s Hospital (Tokyo, Japan)
Adverse events ¥170,831($1,708) ¥85,416 ¥256,247 St. Luke’s Hospital (Tokyo, Japan), [24]
Patient time and transportation ¥68,500($685) ¥34,250 ¥102,750 St. Luke’s Hospital (Tokyo, Japan)
Surveillance (2 visits/year) ¥25,416($254) ¥12,708 ¥38,124 [23]
Per recurrence per year ¥2,405,924($24,059) ¥1,202,962 ¥3,608,886 [22]
Quality of life
No recurrence, no aCT 0.98 0.78 1.00 [23]
Progression 0.30 0.24 0.36 [26,27]
QALY tariff of aCT 0.53 0.43 0.64 [23,24,28]
Other assumptions
Age 49.8 35 75 St. Luke’s Hospital (Tokyo, Japan)
Annual mortality risk after progression 40% 20% 60% [22,23]
Time horizon, years Lifetime ISPOR guidelines
Abbreviations: ¥, JPY Japanese Yen, $, USD United States Dollar, aCT adjuvant chemotherapy, QALY quality-adjusted–life-year, ISPOR International Society For
Pharmacoeconomics and Outcomes Research.
A 3% time preference discount rate was applied in the basecase scenario (lower bound, 1%; upper bound, 5%) [21].
*Per patient on average. Reported in 2013 currency. Conversion rate is 100 JPY per 1 USD.
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related to adjuvant chemotherapy.
Quality of life
Health utility scores and quality-adjusted–life-year (QALY)
tariffs were used to calculate QALYs. Health utility
scores range from 0 for death to 1 for perfect health and
quantify the desirability of a particular health state.
QALY tariffs represent the reduction in QALYs caused
by a procedure or event. These measures of patient pre-
ference and quality-of-life were extracted from published
cost-effectiveness analyses in Japan and time-trade-offpatient surveys (Table 2) [23,26-28]. QALYs were com-
puted as the lifetime sum of the product of each health
state utility and mean time in that health state (adjusted
for fixed annual discount rate).
Data analysis
The changes in QALYs related to the immediate disutility
of adjuvant chemotherapy and the later disutility of re-
currence were analyzed. The lifetime costs and cost-
effectiveness of the 21-gene assay versus current clinical
practice were also reported. The main analysis employed
estimates of distant recurrence risk from a Japanese
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evaluated with estimates of distant recurrence risk from
US- and UK-based clinical validation studies [11,14].
One-way sensitivity analyses were conducted to assess
the robustness of the primary endpoint (cost per QALY
gained). Each parameter was varied across its individual
range to evaluate the effect of the parameters’ uncer-
tainty on the results. The range for each parameter was
extracted from 95% confidence intervals if reported, and
broad ranges (±25% to ±50%) otherwise.
Results
Reduction in adjuvant chemotherapy use (19%) due to the
21-gene assay led to immediate gains of 0.103 QALYs per
patient (Table 3). The 21-gene assay increased adjuvant
chemotherapy use and reduced distant recurrence risk
among high-risk patients, resulting in an additional aver-
age later-term gain of 0.139 QALYs per patient, assuming
baseline risk estimates from the Japanese validation study
(Table 3a). In total, the 21-gene assay led to an average in-
crease of 0.241 QALYs per patient.
The 21-gene assay cost ¥350,000. Reductions in costs
associated with adjuvant chemotherapy (−¥108,041), ad-
verse events (−¥32,852), patient time and transportation
(−¥13,173), and distant recurrence (−¥46,113) offset the
testing cost. Delay and/or prevention of recurrence in-
creased monitoring costs by ¥3,744. Total lifetime costs
increased ¥153,565 per patient with the 21-gene assay,
resulting in an incremental cost-effectiveness ratio of
¥636,752 ($6,368) per QALY gained.
In the alternative analysis, assuming the higher US and
UK baseline distant recurrence risk estimates, the 21-
gene assay increased QALYs by 0.160 years per patient
on average (Table 3b). The QALY increase related to
recurrence-free–survival improvement was smaller in
this scenario (0.057) due to the greater likelihood of
recurrence.
Lifetime costs in this alternative scenario increased by
¥180,369 per patient on average with the 21-gene assay.
Monitoring costs increased by ¥1,537, while the costs to
manage distant recurrence decreased by ¥17,102. Other
costs were identical to the main analysis. The higher US
and UK recurrence risks lead to less recurrence-related
savings and a smaller increase in monitoring costs, re-
sulting in a greater increase in lifetime costs compared
to the main analysis. The cost per QALY gained in the
alternative scenario was ¥1,129,442 ($11,294).
With Japanese distant recurrence risk data, the param-
eters whose change or uncertainty most altered the cost
per QALY gained in the one-way sensitivity analysis were
the: (1) cost of chemotherapy drugs, (2) cost of the 21-
gene assay, and (3) patient’s age at diagnosis (Figure 2).
The maximum cost per QALY gained was ¥1,189,962
($11,900), which resulted only if the average age ofdiagnosis rose from 49.8 to 75. The next highest cost per
QALY gained, ¥1,177,069 ($11,771), resulted only if the
relative distant recurrence risk reduction due to chemo-
therapy in low-risk patients (the fourth most influential
variable) was increased from the base-case value of zero
to 54%. These were the only two scenarios under which
the projected cost per QALY gained was above ¥1,000,000.
Given US- and UK-based distant recurrence risk data,
the parameters whose change or uncertainty most al-
tered the cost per QALY gained were the: (1) relative
distant recurrence risk reduction due to chemotherapy
in low-risk patients and (2) in intermediate-risk patients,
and (3) cost of chemotherapy drugs (Figure 3). Once
again, increasing the relative distant recurrence risk re-
duction due to chemotherapy in low-risk patients from
zero to 54% results in the highest cost per QALY gained.
This scenario’s cost per QALY gained was unusually high
at ¥10,142,498 ($101,425); the next highest cost per
QALY gained was ¥3,703,793 ($37,038), which resulted
when the relative distant recurrence risk reduction due
to chemotherapy in intermediate risk patients was in-
creased from 39% to 76%.
Cost-savings were predicted with the 21-gene assay
when adjuvant chemotherapy drug costs increased beyond
¥1,360,351 ($13,604) given Japanese distant recurrence
risk data. With US- and UK-based distant recurrence data,
cost-savings were predicted when adjuvant chemotherapy
drug costs exceeded ¥1,499,733 ($14,997). These values
were comparable to the drug costs of some regimens con-
taining prophylactic granulocyte colony-stimulating factor
(G-CSF) reported by Ishiguro et al. in 2010 [22].
Discussion
Using actual chemotherapy recommendations in a Japanese
setting, this study found that the use of the 21-gene assay
resulted in an increase of 0.241 QALYs and increased life-
time costs of ¥153,565 per patient on average. The con-
sequent cost per QALY gained was ¥636,752 ($6,368).
Previously, 21-gene assay recommendations were com-
pared with St. Gallen guideline criteria in a societal cost-
effectiveness analysis by Kondo et al. [23]. Guidelines have
been used as surrogate decision impact parameters in
cost-effectiveness studies of diagnostics early in their
development or diffusion when use is fairly limited [29].
As clinical decision impact data becomes available, it is
important to validate those analyses that used surrogate
parameters, as has been done for the 21-gene assay
in other settings [30,31]. The study herein built upon
previous work to provide the first available societal cost-
effectiveness estimate in Japan, applying actual recom-
mendations for chemotherapy from a tertiary referral
center. This study included direct chemotherapy- and dis-
tant recurrence-related costs, and indirect costs associated
with time dedicated to treatment and transportation fees.
Table 3 Base-case results
A. Baseline recurrence risk from a Japan-based validation study
Main analysis Without 21-gene assay With 21-gene assay Difference
Proportion receiving adjuvant chemotherapy 46.2% 26.9% −19.2%
10-year recurrence-free survival, % 94.5% 95.0% 0.5%
QALYs
Adjuvant chemotherapy (immediate) −0.246 −0.144 0.103
Recurrence (long-term) 21.093 21.231 0.139
Total 20.847 21.088 0.241
Costs*
21-gene assay ¥350,000 ¥350,000
Acute costs
Chemotherapy drugs ¥259,298 ¥151,257 -¥108,041
Adverse events ¥78,845 ¥45,993 -¥32,852
Patient time and transportation ¥31,615 ¥18,442 -¥13,173
Monitoring costs until recurrence ¥520,493 ¥524,238 ¥3,744
Costs after recurrence ¥347,446 ¥301,333 -¥46,113
Total ¥1,237,698 ¥1,391,263 ¥153,565
Cost per QALY gained JPY ¥636,752
USD $6,368
B. Baseline recurrence risk from US- and UK-based validation studies
Alternative analysis Without 21-gene assay With 21-gene assay Difference
Proportion receiving adjuvant chemotherapy 46.2% 26.9% −19.2%
10-year recurrence-free survival, % 89.4% 89.6% 0.3%
QALYs
Adjuvant chemotherapy (immediate) −0.246 −0.144 0.103
Recurrence (long-term) 19.533 19.590 0.057
Total 19.287 19.447 0.160
Costs*
21-gene assay ¥350,000 ¥350,000
Acute costs
Chemotherapy drugs ¥259,298 ¥151,257 -¥108,041
Adverse events ¥78,845 ¥45,993 -¥32,852
Patient time and transportation ¥31,615 ¥18,442 -¥13,173
Monitoring costs until recurrence ¥478,260 ¥479,798 ¥1,537
Costs after recurrence ¥899,695 ¥882,593 -¥17,102
Total ¥1,747,715 ¥1,928,084 ¥180,369
Cost per QALY gained JPY ¥1,129,442
USD $11,294
Abbreviations: QALY quality-adjusted–life-year, ¥, JPY Japanese Yen, $, USD United States Dollar.
*Per patient on average. Reported in 2013 currency.
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per QALY gained was less than ¥1,189,962 ($11,900)
across all ranges of parameters. The cost-effectiveness
ratio was highest when patient age at diagnosis was high
or chemotherapy was assumed to be extremely beneficial
for low-risk patients. The 95% confidence interval forthe effect of chemotherapy in low-risk patients was very
wide, and 84% of that range indicated no benefit to
chemotherapy for low-risk patients [15].
The largest change in the cost per QALY gained in the
one-way sensitivity analysis resulted when the cost of
chemotherapy drugs was varied. This finding is especially
Figure 2 One-way sensitivity analysis tornado diagram: baseline recurrence risk from a Japan-based validation study. Abbreviations:
aCT, adjuvant chemotherapy; AEs, adverse events; QALY, quality-adjusted–life-year; ¥, JPY, Japanese Yen in 2013 currency.
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recently been reported to have a cost-effectiveness ratio
lower than the commonly accepted threshold value (¥6
million per QALY gained) [22]. If adjuvant chemotherapy
drug costs increase to the values previously reported for
G-CSF–containing chemotherapy regimens in Japan, this
model shows that the 21-gene assay would be cost-saving,
regardless of the distant recurrence risk data source.
The 21-gene assay validation study in Japan showed no
distant recurrences in the intermediate-risk group [17].
Therefore, the benefit of chemotherapy for the interme-
diate group had no effect on the cost or QALY results in
the main analysis. By contrast, US- and UK-based valida-
tion studies showed higher distant recurrence risks over-
all, increasing from the low- to intermediate- to high-risk
groups. When estimates from the US- and UK-basedFigure 3 One-way sensitivity analysis tornado diagram: baseline recu
Abbreviations: aCT, adjuvant chemotherapy; AEs, adverse events; QALY, quastudies were applied, varying the benefit (relative risk re-
duction) due to chemotherapy in the intermediate-risk
group in the one-way sensitivity analysis led to the
second-largest change in the cost per QALY gained result.
Applying real chemotherapy recommendation changes,
this analysis’ findings differed from those of a previous
analysis by Kondo et al. in several significant respects [23].
Total QALYs were slightly higher in this study (20.8 years
without and 21.1 years with the 21-gene assay) than in
Kondo et al. (19.5 years without and 20.1 years with);
however, the QALYs gained in this study (0.241) was less
than half of that reported by Kondo et al. (0.63). In this
analysis, the lifetime costs do not exceed ¥2 million in any
of the scenarios tested regardless of 21-gene assay use,
whereas Kondo et al. reported costs exceeding ¥3 million.
Using US- and UK-based recurrence risk estimatesrrence risk from a US- and UK-based validation studies.
lity-adjusted–life-year; ¥, JPY, Japanese Yen in 2013 currency.
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QALYs was 19.3 years without and 19.4 years with the
21-gene assay, slightly below those reported by Kondo
et al. The 0.160 QALY gain projected here is approxi-
mately one-fourth of the gain estimated by Kondo et al.
Factors that may have led to the differences include (1) a
larger decrease in recommendations in favor of adjuvant
chemotherapy found in actual clinical practice (19%
herein versus 8% when applying St. Gallen criteria) and
(2) a target population selection that excluded patients
with HER2+ tumors who would presumably receive tras-
tuzumab regardless of the 21-gene assay result. Given the
unexplained differences among these model findings, it
may be a useful exercise to directly and collaboratively
cross-validate the available models, as has been performed
in other fields [32].
Several limitations are important to consider when
interpreting the results of this study. First, the decision
impact study at the tertiary center excluded women (1)
whose recurrence risk was assessed by a physician as
very low, (2) who had already chosen to undergo che-
motherapy, or (3) who could not afford to participate.
Therefore, the proportion of patients whose treatment
recommendations are altered by the 21-gene assay may
be different if the assay were used without consideration
of these exclusion criteria. Second, utilities estimates
from Japanese women are not available. For more than
two decades, it has been well-established that attitudes
about cancer and its treatments may differ across coun-
tries [33]. It would be relevant in the future to have in-
formation from studies on patients’ experiences in Japan,
especially utility data. Finally, the 21-gene assay has re-
cently been shown to also predict local recurrence [13].
Excluding this outcome benefit predictably under-
estimates the benefits to patients and cost-savings to
society. This analysis likely overestimated the cost per
QALY gained with the 21-gene assay compared to clini-
cal practice using traditional clinicopathological factors.
Conclusions
Previous analyses concluded that the 21-gene assay “is
indicated as cost-effective in Japan” when compared to
clinical guidelines [23]. This new analysis, which incor-
porated clinical recommendations made in Japanese ter-
tiary referral centers, supports this finding.
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